The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor by van Dijk, F. et al.
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
The antiﬁbrotic potential of a sustained release formulation of a PDGFβ-
receptor targeted rho kinase inhibitor
F. van Dijka,b, N. Teekampa, E. Postb, D. Schuppanc,d, Y.O. Kimc, J. Zuidemae, R. Steendame,
Matthias H.M. Klosei, Samuel M. Meier-Menchesf,i, A. Casinif, P.L. Horvatovichg, N.J. Sijbrandih,
H.W. Frijlinka, W.L.J. Hinrichsa, K. Poelstrab, L. Beljaarsb, P. Olingaa,⁎
aGroningen Research Institute of Pharmacy, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
bGroningen Research Institute of Pharmacy, Department of Pharmacokinetics, Toxicology and Targeting, University of Groningen, Groningen, The Netherlands
c Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany
d Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
e InnoCore Pharmaceuticals, Groningen, The Netherlands
f School of Chemistry, Cardiﬀ University, Park Place, CF10 3AT, Cardiﬀ, UK
gGroningen Research Institute of Pharmacy, Department of Analytical Biochemistry, University of Groningen, Groningen, the Netherlands
h LinXis BV, Amsterdam, The Netherlands
iDepartment of Analytical Chemistry, University of Vienna, Waehringer Straße 38, 1090 Vienna, Austria
A R T I C L E I N F O
Keywords:
Controlled release
Polymeric microspheres
Protein delivery
Drug targeting
Biologicals
Liver ﬁbrosis
A B S T R A C T
Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction
of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of
rho kinase activity can reduce these activities, but may also lead to side eﬀects, for instance systemic hypo-
tension. This can be circumvented by liver-speciﬁc delivery of a rho kinase inhibitor to eﬀector cells. Therefore,
we targeted the rho kinase inhibitor Y27632 to the key pathogenic cells in liver ﬁbrosis, i.e. myoﬁbroblasts
including activated HSCs that highly express the PDGFβ-receptor, using the drug carrier pPB-MSA. This carrier
consists of mouse serum albumin (MSA) covalently coupled to several PDGFβR-recognizing moieties (pPB). We
aimed to create a prolonged release system of such a targeted construct, by encapsulating pPB-MSA-Y27632 in
biodegradable polymeric microspheres, thereby reducing short-lasting peak concentrations and the need for
frequent administrations. Firstly, we conﬁrmed the vasodilating potency of PDGFβ-receptor targeted Y27632 in
vitro in a contraction assay using HSCs seeded on a collagen gel. We subsequently demonstrated the in vivo
antiﬁbrotic eﬃcacy of pPB-MSA-Y27632-loaded microspheres in the Mdr2−/− mouse model of progressive
biliary liver ﬁbrosis. A single subcutaneous microsphere administration followed by organ harvest one week
later clearly attenuated liver ﬁbrosis progression and signiﬁcantly suppressed the expression of ﬁbrosis related
genes, such as several collagens, proﬁbrotic cytokines and matrix metalloproteinases. In conclusion, we de-
monstrate that polymeric microspheres are suitable as drug delivery system for the sustained systemic delivery
of targeted protein constructs with antiﬁbrotic potential, such as pPB-MSA-Y27632. This formulation appears
suitable for the sustained treatment of liver ﬁbrosis and possibly other chronic diseases.
1. Introduction
In advanced liver ﬁbrosis, scarring and contraction of ﬁbrogenic
cells leads to portal hypertension due to increased hepatic resistance to
portal inﬂow, representing one of the major complications of cirrhosis
[1,2]. On the other hand, cirrhosis is commonly associated with a re-
duced mean arterial pressure due to peripheral vasodilation, causing an
increase in splanchnic ﬂow, which severely compromises options for
treatment [2,3].
Upregulation of intrahepatic rho-associated protein kinase activity
(here termed rho kinase), contributes to the development of portal
hypertension in liver cirrhosis [4,5]. Rho kinase is a major downstream
eﬀector protein of Rho GTPase, and is involved in cell migration and
contractility of diﬀerent cell types [6,7]. Inhibition of this protein using
rho kinase inhibitors, such as Y27632, reduced portal vascular re-
sistance and thus portal pressure [5,8]. In addition to these
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hemodynamic eﬀects, Y27632 was shown to possess antiﬁbrotic ac-
tivity in several animal models of liver ﬁbrosis [9–11]. However, sys-
temic administration of a rho kinase inhibitor will aﬀect many cell
types in diﬀerent organs, as rho kinase-controlled signaling occurs in
virtually every cell type. This may cause adverse eﬀects, including a
reduction in vascular smooth muscle contractility and therefore a fur-
ther decline in the already low systemic blood pressure in cirrhotics
[8,12].
This side eﬀect can be circumvented by the cell-speciﬁc delivery of a
rho kinase inhibitor to the key pathogenic organ and cells, preventing
eﬀects on other cells such as vascular smooth muscle cells. The pa-
thogenic cells involved in the excessive production of extracellular
matrix (ECM) proteins in liver ﬁbrosis are hepatic stellate cells (HSCs)
and myoﬁbroblasts that show a contractile phenotype [13]. These cells
can be reached by targeting their exclusively expressed PDGFβ-re-
ceptors with an albumin-based drug carrier (pPB-MSA). pPB-MSA is
composed of several PDGFβ-receptor recognizing peptides (pPB) at-
tached to an albumin core (mouse serum albumin, MSA) [14,15]. By
inhibiting rho kinase activity speciﬁcally in the target cells, their mi-
gration, contraction and excess extracellular matrix production can be
impeded. The antiﬁbrotic eﬀect of the rho kinase inhibitor Y27632
when targeted to the myoﬁbroblasts using the similar albumin carrier
M6P-HSA binding to the mannose 6-phosphate/insulin-like growth
factor II (M6P/IGFII) receptor was previously demonstrated [7]. The
inhibitor was coupled to the carrier via a platinum-based linker, al-
lowing slow intracellular release of Y27632 from the conjugate during
several days after endocytic uptake [7,16]. The same rho kinase in-
hibitor and linker were successfully used before to target the ﬁbrotic
kidney [17].
An essential challenge in the application of therapeutic proteins is
the route of administration. For such drugs the most common route is
parenteral administration, generally causing undesirable ﬂuctuations in
plasma levels and moreover the need for repeated parenteral injections;
a high burden to the patient [18]. Therefore, in addition to the for-
mation of an intracellular slow release depot of Y27632 by taking ad-
vantage of the properties of the chemical linker, a patient-friendly
formulation providing gradual and prolonged release of such ther-
apeutic proteins for application in chronic diseases such as ﬁbrosis may
ensure sustained release [19]. We previously established the sustained
controlled release of a similar albumin-based carrier lasting for at least
7 days in vivo by encapsulating the protein in biodegradable polymeric
microspheres [20] and explored the pharmacokinetic release proﬁle
[15]. We were able to demonstrate long lasting serum levels of the
carrier and its localization in the ﬁbrotic organ.
In the present study, we explored the pharmacodynamic properties
of biodegradable polymeric microspheres loaded with the albumin-
based carrier (pPB-MSA) coupled to an antiﬁbrotic compound (Y27632)
via the platinum-based Lx-linker. We ﬁrst assessed the relaxing poten-
tial of pPB-MSA-Y27632 in vitro. Subsequently, we prepared polymeric
microspheres containing pPB-MSA-Y27632 that allow release of pro-
teins for at least 7 days and conﬁrmed its antiﬁbrotic activity at 7 days
after a single microsphere injection in Mdr2−/−mice with progressive
biliary liver ﬁbrosis.
2. Materials and methods
2.1. Synthesis and characterization of proteins
pPB-MSA was synthesized as described in the supplemental mate-
rials and methods [14,15]. The Lx-linker (LinXis, Amsterdam, the
Netherlands) was used as platinum-based linker to couple Y27632 to
pPB-MSA. The Lx-linker was conjugated to trans-4-[(1R)-1-Ami-
noethyl]-N-4-pyridinylcyclohexanecarboxamide dihydrochloride, i.e.
Y27632 (Tocris Bioscience, Bristol, UK), and characterized with NMR,
mass spectrometry and HPLC as described in the supplemental mate-
rials and methods, and was subsequently coupled to pPB-MSA. In short,
0.214 μmol Y27632-Lx reacted with 14 nmol pPB-MSA in 20mM tri-
cine/NaNO3 buﬀer pH 8.5 for 30min at room temperature while stir-
ring, and subsequently incubated overnight at 37 °C. The mixture was
dialyzed against PBS for 48 h, and freeze dried.
The product was characterized by silver staining and MALDI-TOF
mass spectrometry (Voyager DE-Pro MALDI-TOF, Applied Biosystems,
Foster City, CA, USA) in a sinapinic acid matrix according to standard
protocols. The molecular weight range was estimated from the obtained
spectra at a cutoﬀ of 30% of the maximum intensity, at which the
background noise was exceeded. For the silver staining, samples (10 μg)
were applied on a 10% SDS polyacrylamide gel according to standard
procedures. In short, the gel was ﬁxed in H2O/MeOH=1/1 containing
acetic acid. After washing in 25% EtOH in H2O, the gel was incubated
in H2O containing Na2S2O3. Next, the gel was extensively washed in
H2O, incubated in H2O supplemented with AgNO3 and formaldehyde,
washed again and developed in H2O containing Na2S2O3, formaldehyde
and Na2CO3. The reaction was stopped by washing and subsequent
incubation in H2O/MeOH=4/5 containing acetic acid, after which the
gel was photographed.
2.2. Contraction assay
Human LX2 hepatic stellate cells were kindly provided by Prof.
Scott Friedman (Mount Sinai Hospital, New York) and cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, Invitrogen, Carlsbad, CA)
supplemented with 10% FCS and antibiotics (100 U/ml penicillin and
100 μg/ml streptomycin). Cells (50.000/well) were seeded in complete
medium containing 2% FCS on collagen gels, composed of 1.2mg/ml
collagen I (rat tail, Corning, New York), 6 mM NaOH, 0.4× PBS (55mM
NaCl, 1 mM KCl, 4 mM PO43−, pH 7.4) and 20mM HEPES diluted in
medium, which were allowed to solidify for 1 h at 37 °C and 5% CO2.
After 3 h, the medium was replaced by complete medium and cells
incubated with 10 μM Y27632, pPB-MSA-Y27632 or pPB-MSA for 48 h.
Gels were photographed and contraction was determined as the ratio
between the surface of the gel and the surface of the well as measured
with ImageJ (National Institutes of Health, USA).
2.3. Production and characterization of microspheres
Microspheres were produced using a similar double emulsiﬁcation
evaporation method as described previously [20]. The used polymers
are phase-separated multi-block copolymers, composed of poly(L-lac-
tide) (PLLA), poly ethylene glycol (PEG) and poly(ε-caprolactone)
(PCL). The copolymers [PCL-PEG1000-PCL]-[PLLA] (50/50 weight ratio)
and [PCL-PEG3000-PEG]-[PLLA] (30/70 weight ratio) (obtained from
InnoCore Pharmaceuticals, Groningen, The Netherlands) were used at a
1:1 weight ratio. PBS (control), or pPB-MSA-Y27632 and MSA in a 1:4
weight ratio, or pPB-MSA and MSA in a 3:2 weight ratio were en-
capsulated at a 5 wt-% theoretical protein load. Microspheres were
characterized for morphology by scanning electron microscopy, particle
size distribution by laser diﬀraction, protein content and in vitro protein
release as described before by Teekamp et al. [20].
2.4. Animal experiments
Experiments with the Mdr2−/− mouse model were approved by
the Animal Ethical Committee of the State of Rhineland Palatinate.
Female FVB mice (n=8) were purchased from Jackson Laboratory
(Jackson Laboratory, Bar Harbor, ME, USA) and FVB Mdr2−/− mice
(n=26) (20–26 g) were bred in homozygosity at the Institute of
Translational Immunology at Mainz University Medical Center. All
animals were housed with a 12 h light/dark cycle with ad libitum chow
and water. At age 8–9weeks, Mdr2−/− mice were injected sub-
cutaneously in the neck. Mice received 500 μl of 0.4% carboxymethyl
cellulose (CMC, Aqualon high Mw, Ashland, pH 7.0–7.4) containing
either 63mg microspheres encapsulating 3 wt-% pPB-MSA+2 wt-%
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MSA (n=8), or 100mg microspheres encapsulating 1 wt-% pPB-MSA-
Y27632+4 wt-% MSA (n=4) or no protein (polymer only) (n=8).
Another group of mice was injected subcutaneously once daily for
7 days with 250 μg/ml Y27632 (Tocris Bioscience, Bristol, UK) in PBS
for a ﬁnal dose of 1mg/kg (n=6). All mice were sacriﬁced 7 days after
microsphere administration or after 7 injections with plain Y27632.
Livers were collected for further analysis.
2.5. Inductively coupled plasma mass spectrometry
The platinum content in the livers was quantitated with inductively
coupled plasma mass spectrometry (ICP-MS), using an ICP-MS Agilent
7500ce (Agilent Technologies, Waldbronn, Germany) instrument,
equipped with a CETAC ASC-520 autosampler (CETAC Technologies,
Omaha, Nebraska, USA) and a MicroMist nebulizer at a sample uptake
rate of 0.25ml/min. The instrument was calibrated on a daily basis.
Platinum and rhenium standards for ICP-MS measurements were de-
rived from CPI International (Amsterdam, The Netherlands). ICP-MS
parameters were: RF power 1560W, cone material nickel, carrier gas
0.9–1.0 l/min, make up gas 0.2–0.3 l/min, plasma gas 15 l/min, dwell
time 0.3 s, replicates 10, monitored isotopes 194Pt and 195Pt. The
Agilent MassHunter software package (Workstation Software, version
B.01.01, Build 123.11, Patch 4, 2012) was used for data processing.
Samples were prepared by digestion of 15–30mg tissue, gravimetrically
weighted, in 2ml 20% nitric acid using a microwave system (Discover
SP-D, CEM Microwave Technology, Germany) (200 °C, ramp time
5min, hold time 6min, maximal power 300W). Digested samples were
diluted with ultrapure water (18.2 MΩ cm, Milli-Q Advantage,
Darmstadt, Germany) resulting in nitric acid concentrations< 4% and
platinum concentrations< 15 μg/kg.
2.6. Low density array
Total RNA was isolated from livers using a Maxwell® LEV simply
RNA Cells/Tissue kit (Promega, Madison, WI, USA) according to man-
ufacturer's instructions. RNA concentrations were determined using
NanoDrop One spectrophotometer (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). The expression of 27 ﬁbrosis-related genes (supplementary
table 1) was studied with a custom-designed low density array. For this,
a reaction mixture containing 50 μl of 6 ng/μl cDNA and 50 μl 2×
TaqMan PCR Master Mix was loaded per sample. PCR ampliﬁcation was
performed on a ViiA7 Real-Time PCR system (all Applied Biosystems).
For each sample, mRNA expression was normalized for GAPDH, β-actin
and YWHAZ. Fold induction values were calculated using the 2^-ΔΔCt
method and subsequently Z-normalized [21]. For this, the mean 2^-
ΔΔCt and the standard deviation of the 2^-ΔΔCt values of each popu-
lation were calculated. Z-normalization was performed by subtracting
the mean from each 2^-ΔΔCt value in a population, and subsequently
dividing these values by the standard deviation. Heat maps for diﬀerent
sets of genes were generated using R Studio (version 1.1.383).
2.7. Immunohistochemistry
Paraﬃn sections of livers were cut with a Leica Reichert-Jung 2040
microtome (Leica Microsystems, Nussloch, Germany) with a thickness
of 4 μm. The sections were deparaﬃnized in xylene and ethanol.
Sections were rehydrated in PBS and were incubated for 1 h with the
primary antibodies (goat anti-collagen I&III (both 1:200+ 5% normal
mouse serum (Southern Biotech, Birmingham, AL, USA)) at room
temperature. Next, sections were incubated with the appropriate HRP-
conjugated secondary antibody (1:100, DAKO, Santa Clara, CA, USA)
for 30min at room temperature and were visualized with ImmPACT
NovaRED (both Vector, Burlingame, CA, USA). Hematoxylin counter-
staining was performed. Digital photomicrographs were captured at
400× magniﬁcation, and quantiﬁed using Aperio ImageScope software
12.3.2.8013 (all Aperio, Vista, CA, USA). The total intensity of strong
positive pixels was determined per surface area of liver tissue (μm2),
excluding sclerosing bile ducts.
2.8. Statistical analyses
At least 3 individual experiments were performed for the in vitro
microsphere characterization. All data are represented as
mean ± SEM. The graphs were made with Graphpad Prism version 8
(GraphPad Prism Software, Inc., La Jolla, CA, USA). The statistics were
performed with R (version 3.4.0, 2017-04-21, 64 bit). Statistical dif-
ferences were assessed by Kruskal Wallis test, and if applicable pairwise
comparison was done by Mann-Whitney test corrected with Benjamini-
Hochberg test, unless stated otherwise in the ﬁgure caption.
3. Results
3.1. Characterization of pPB-MSA-Y27632
The rho kinase inhibitor Y27632 was coupled to pPB-MSA as HSC-
selective drug carrier using the platinum-based Lx-linker.
Characterization of the constructs using silver staining and MALDI-TOF
mass spectrometry showed monomeric protein products with average
molecular weights of 66,0 kDa, 71,0 kDa and 73,6 kDa for MSA, pPB-
MSA and pPB-MSA-Y27632, respectively (Fig. 1, Table 1, Fig. S1).
Based on these data, we calculated that per mouse albumin molecule
approximately 5 pPB-moieties (MW=1 kDa) and 5 Y27632 molecules
(MW=538 Da) were coupled (Table 1).
3.2. In vitro eﬀect of pPB-MSA-Y27632
To verify the in vitro activity of pPB-MSA-Y27632, we assessed the
relaxing potency of targeted Y27632 in a contraction assay using LX2
hepatic stellate cells seeded on a collagen gel (Fig. 2A and B), as rho
kinase is known to be particularly involved in cell contractility. Both
pPB-MSA-Y27632 and free Y27632 (in equimolar amounts) sig-
niﬁcantly reduced the contractility of LX2 cells after 48 h by
38.7 ± 8.4% and 41.0 ± 5.5%, respectively. The carrier pPB-MSA
alone did not aﬀect cell contraction. These results indicate that PDGFβ-
receptor directed Y27632 is able to exert its eﬀect in the designated
target cells.
3.3. Microsphere characterization
We continued our studies with the development of a sustained re-
lease formulation aiming for at least 7 days of gradual release of pPB-
MSA-Y27632. For this, we prepared polymeric microspheres and en-
capsulated our construct as described before [15,20]. The microspheres
displayed a polydisperse size distribution and a median particle size of
27.9 μm (Fig. 3B, Table 2). Control microspheres containing either pPB-
MSA or no protein were slightly smaller in size, with median sizes of
21.6 and 22.0 μm, respectively. Scanning electron microscopy showed
that all particles were spherical with a smooth surface (Fig. 3A) and
Fig. 1. Analysis of MSA-based protein constructs using silver staining. M de-
notes molecular weight marker.
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analysis of the protein content of the microspheres revealed a high
encapsulation eﬃciency of 81% for pPB-MSA-Y27632-loaded micro-
spheres and 103% for pPB-MSA encapsulated particles (Table 2). The in
vitro release proﬁle of proteins from the pPB-MSA-Y27632 microspheres
revealed sustained and gradual release for several days, with only a
minimal initial burst release. The cumulative protein release from pPB-
MSA-Y27632-loaded microspheres in release buﬀer was 78 ± 2.9%
after 14 days (Fig. 3C). The morphology and in vitro release character-
istics of pPB-MSA-loaded microspheres were published before [15].
3.4. In vivo antiﬁbrotic eﬀects of pPB-MSA-Y27632-loaded microspheres
The microspheres containing pPB-MSA-Y27632 were injected once
subcutaneously in Mdr2−/− mice aged 8–9weeks, suﬀering from
advanced biliary liver ﬁbrosis. At 7 days after injection, we were able to
detect levels of 721 ± 23 ng platinum/liver, reﬂecting the presence of
the Lx-linker as part of pPB-MSA-Y27632. We performed a gene array
on liver samples of these mice, and observed that the gene expression
levels for the extracellular matrix proteins (collagens 1a1, 1a2, 3a1,
4a1, 5a1 and 6a1, elastin and ﬁbronectin 1) were signiﬁcantly reduced
(p=0.001) in the group of mice treated with microspheres containing
pPB-MSA-Y27632 as compared to mice that received empty micro-
spheres (Fig. 4A). Moreover, gene expression levels for the proﬁbro-
genic cytokines (transforming growth factor beta 1 (TGFβ-1) and pla-
telet-derived growth factor BB (PDGF-BB)) and matrix
metalloproteinases MMP-2 and -14 were markedly reduced (p=0.026
and 0.021, respectively) following treatment with pPB-MSA-Y27632-
loaded microspheres as compared to diseased control animals that re-
ceived empty microspheres (Fig. 4B and C, respectively), as demon-
strated by the reduced z-normalized values and the accessory heat maps
(expression of the separate genes is shown in Fig. S2). The treatment did
not aﬀect the expression levels of proteoglycans (decorin, biglycan and
ﬁbromodulin), proinﬂammatory cytokines (interleukin 1β, tumor ne-
crosis factor and chemokine ligand 2), proteases (cathepsin K, bone
morphogenetic protein 1 and ADAMTS2) or protease inhibitors (TIMP2,
plasminogen activator inhibitor 1) (data not shown). The antiﬁbrotic
eﬀect on ECM proteins was conﬁrmed at the protein level by im-
munohistochemical staining for collagen I&III, that clearly demon-
strated regression of bridging ﬁbrosis in the liver parenchyma of mice
treated with pPB-MSA-Y27632-containing microspheres as compared to
the control groups (empty MSP or pPB-MSA MSP) or plain Y27632
(Fig. 5A and B).
Free Y27632 injected subcutaneously once daily did not have any
antiﬁbrotic eﬀect in the livers of these mice. Previous studies did show
an eﬀect of Y27632 on liver ﬁbrosis [7], albeit to a lesser extent than
the targeted equivalent, but in these studies free Y27632 was ad-
ministered intravenously.
4. Discussion
Kinase inhibitors seem promising for future treatment of ﬁbrotic
diseases, as they inhibit the proliferation and contractility of the key
pathogenic cells in liver ﬁbrogenesis, i.e. the myoﬁbroblasts including
activated hepatic stellate cells (HSCs) [22]. In particular, the rho kinase
inhibitor Y27632 was shown both in vitro and in vivo to eﬀectively re-
duce ﬁbrotic parameters [9–11,23]. Despite its antiﬁbrotic potential,
this kinase inhibitor induced several serious adverse eﬀects [8,12].
Therefore, in our studies we aimed to deliver Y27632 to the HSCs that
control the excessive extracellular matrix (ECM) protein deposition and
blood ﬂow in the cirrhotic liver. We delivered this compound to the
ﬁbrogenic and contractile cells by targeting the highly and speciﬁcally
expressed PDGFβ-receptor [24], after attaching multiple Y27632 moi-
eties to the HSC-selective drug carrier pPB-MSA [14,15]. The receptor
selectivity and preferential localization of the human equivalent and
several similar constructs based on the same targeting moiety were
already demonstrated before both in vitro and in vivo in various studies
[14,25,26]. For eﬀective treatment of chronic diseases such as ﬁbrosis
we further developed a patient-friendly formulation that could facilitate
the gradual and prolonged release of this pPB-MSA-Y27632, thereby
circumventing high plasma concentrations following intravenous in-
jections and avoiding multiple administrations [18]. In the present
study, we achieved a sustained release of pPB-MSA-Y27632 from
polymeric microspheres in vitro and moreover demonstrated its pro-
longed antiﬁbrotic activity in vivo.
In in vitro experiments assessing HSCs contractility, we demon-
strated that pPB-MSA-Y27632 was equally active as free Y27632. Our
results are in line with those of previous in vitro studies with Y27632-
constructs targeted to the PDGFβ-receptor or the mannose 6-phos-
phate/insulin-like growth factor II (M6P/IGFII) receptor [7,27]. These
results conﬁrm that our protein construct is pharmacologically active
and also show that in vitro there is no added value to the targeted
Table 1
Characterization of MSA-based protein constructs using MALDI-TOF mass
spectrometry. MW denotes molecular weight of the protein constructs.
Average MW
(Da)
Range MW (Da) # pPB
coupled
# Y27632
coupled
MSA 65,950 65,000–66,850 – –
pPB-MSA 70,950 66,900–77,600 5 –
pPB-MSA-
Y27632
73,570 66,150–80,150 5 5
Fig. 2. The in vitro eﬀect of pPB-MSA-Y27632 as determined by a contraction
assay in cultures of LX2 cells seeded on collagen gels. (A) Representative images
and (B) analysis of the three-dimensional gel contraction assay following
treatment of cells for 48 h with pPB-MSA-Y27632, pPB-MSA or Y27632 (n=4),
relative to vehicle treatment. Dashed circles indicate the margins of the gels
comprising the gel surface areas. Diﬀerences between groups were assessed in
Graphpad Prism version 8 by Friedman test followed by Dunn's multiple com-
parisons test.
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construct as compared to free Y27632.
The used platinum (II)-based Lx-linker, creating a coordinative bond
between the rho kinase inhibitor and pPB-MSA, oﬀers advantages in
terms of synthesis and stability of the construct [16]. It was previously
shown that this linker, when attached to another kinase inhibitor and
carrier protein, after endocytosis could provide a local drug reservoir
for several days following a single injection assuring slow intracellular
release of the drug [16]. This can be explained by the slow ligand-ex-
change kinetics of platinum allowing replacement of attached drugs by
other (intracellular) ligands such as glutathione [28], or by degradation
of the protein part of the construct by cellular enzymes in lysosomes,
enabling the release of the active compound [16]. Ultimately, all the
protein components are degraded. The fate of the Lx-linker is still un-
known, but it will most likely form intracellular conjugates with glu-
tathione [29]. Although platinum-based compounds like cisplatin are
notorious nephrotoxic agents, this particular platinum (II)-based linker
did neither induce any toxicity in vitro in amongst others renal tubular
cells nor in vivo in the kidneys [16]. This is due to the relatively low
concentrations of the linker (far below toxicity levels) and to the fact
that platinum is not present in its unconjugated (free) form; it is either
coupled to albumin or to intracellular ligands like glutathione [29].
Previous studies using the same Lx-linker demonstrated the anti-
ﬁbrotic potential of Y27632 in vivo when targeted to the M6P/IGFII-
receptor expressed on activated HSCs in the CCl4 model of parenchymal
liver ﬁbrosis [7]. Also, when Y27632 was coupled to the renal-speciﬁc
protein lysozyme via the aforementioned linker, a signiﬁcant reduction
in renal ﬁbrotic parameters was observed in the ischemia/reperfusion
injury rat model [17]. Moreover, a strong inhibition of tubular damage
and inﬂammation was demonstrated.
The rho kinase inhibitor Y27632 was not the only compound that
was successfully targeted to ﬁbrotic organs including the liver by cou-
pling to carrier molecules using the platinum-based linker technology.
Several studies demonstrated the targeting of other Lx-based constructs
to the liver as well, albeit in diﬀerent species and using animal models
of diﬀerent etiology. The antiﬁbrotic and anti-inﬂammatory eﬀects of
the angiotensin type 1 receptor blocker losartan conjugated to the HSC-
selective drug carrier mannose-6-phosphate modiﬁed human serum
albumin (M6P-HSA) were demonstrated in rats with advanced liver
ﬁbrosis induced by prolonged bile duct ligation or CCl4 administration
[30]. Moreover, the organ speciﬁcity of the construct and colocalization
with activated HSCs being the target cells were demonstrated. In an-
other study, a tyrosine kinase inhibitor (the imatinib derivative PAP19)
was coupled to M6P-HSA using the Lx-linker, in order to reach acti-
vated HSCs in the ﬁbrotic liver, where a reduction in collagen deposi-
tion and activation of HSCs in livers of bile duct ligated rats was found
[31]. Although all described constructs signiﬁcantly reduced several
ﬁbrosis related parameters, the number one choice for the drug to
target will ultimately depend on disease etiology.
In the present study we only focused on the antiﬁbrotic eﬀects of
our formulation, and did not consider other eﬀects such as inﬂamma-
tion or hemodynamic eﬀects. Our group and others previously de-
monstrated that the inhibition of rho kinase with Y27632 in activated
HSCs using several selective carriers, including M6P-HSA and pPB-HSA,
signiﬁcantly decreased portal pressure and hepatic vascular resistance
in diﬀerent animal models of liver cirrhosis with portal hypertension
[4,7,27]. This conﬁrms the importance of rho kinase in the regulation
of the hepatic vascular resistance and blood pressure. Selective inhibi-
tion of rho kinase did not cause any oﬀ-target hemodynamic or toxic
eﬀects [4,27]. The eﬀects on portal pressure and ﬁbrosis were ex-
plained by a reduction in phosphorylation of myosin light chain (MLC)
in HSCs, as one of the downstream proteins in the rho kinase pathway
[4,7,27].
For the future treatment of chronic diseases such as liver ﬁbrosis,
continuous drug release provided by a sustained release formulation
may be crucial in addition to the slow intracellular release governed by
the Lx-linker, because high plasma levels possibly leading to toxicity are
prevented. Moreover, a discontinuous eﬀect of drugs, in the case for rho
kinase inhibitors on for instance portal pressure, may still lead to a
perpetuation of disease activity. An additional beneﬁt of a sustained
release formulation is that multiple injections are not necessary, and
thus patient compliance and comfort are improved [19]. We now were
able to show the pharmacological eﬀects of Y27632 one week after a
Fig. 3. Morphology, particle size distribution and in vitro release of proteins from polymeric microspheres containing pPB-MSA-Y27632. (A) Representative scanning
electron micrograph of pPB-MSA-Y27632-loaded microspheres after freeze-drying (1000× magniﬁcation) showing smooth spherical particles. (B) Particle size
distribution of microspheres with volume percentage on left y-axis (solid line) and cumulative volume percentage on right y-axis (dashed line). (C) Cumulative in vitro
release of proteins from pPB-MSA-Y27632-loaded microspheres as measured with BCA assay. Percentages are corrected for the encapsulation eﬃciency.
Table 2
Characteristics of microspheres with diﬀerent contents used in vivo in the Mdr2−/− model.
Formulation Theoretical protein load Particle size in μm (SEM) Span Encapsulation eﬃciency (%) Total protein load (%) Drugload (Y27632, μg)
X10 X50 X90
pPB-MSA-Y27632 (PMY) 1% PMY/4% MSA 5.7 (0.1) 27.9 (0.2) 67.1 (0.2) 2.2 80.6 4.1 12.4
pPB-MSA 3% pPB-MSA/2% MSA 3.4 (0.1) 21.6 (0.3) 66.7 (0.7) 2.9 103.3 5.2 –
Control – 3.1 (0.0) 22.0 (0.2) 63.9 (0.5) 2.8 – – –
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single subcutaneous injection by applying polymeric microspheres
containing pPB-MSA-Y27632. Thus, by incorporating a high molecular
weight cell-speciﬁc protein in microspheres that enable slow release, an
eﬀective concentration on the target site can be achieved.
The polymeric microsphere formulation was found suitable for the
sustained release of large therapeutic proteins in previous studies. The
polymers that were used to produce the microspheres are biodegrad-
able phase-separated multi-block copolymers, composed of poly(L-lac-
tide) (PLLA), poly ethylene glycol (PEG) and poly(ε-caprolactone)
(PCL), of which the in vivo biocompatibility was shown not to be dif-
ferent from poly(lactic-co-glycolic acid) (PLGA), the FDA-approved
golden standard [33]. Although macrophage inﬁltration into the im-
plantation site occurred over time as part of the foreign body response,
this did not seem to have an eﬀect on the functionality of the micro-
spheres (unpublished data). We studied the in vivo release kinetics of a
similar carrier protein encapsulated in such microspheres, which most
likely reaches the systemic circulation via the lymphatic system, and
subsequent localization in the unilateral ureter obstruction (UUO)
model for kidney ﬁbrosis and the Mdr2−/− model for liver ﬁbrosis
before [15,20].
We proceeded with the same formulation and now encapsulated
pPB-MSA-Y27632, which showed in vitro diﬀusion-controlled sustained
Fig. 4. In vivo eﬀects of pPB-MSA-Y27632 released from subcutaneously residing polymeric microspheres on the gene level. Z-normalized values of fold inductions
(fold inductions are relative to healthy controls) and heat maps of (A) extracellular matrix proteins (collagens 1a1, 1a2, 3a1, 4a1, 5a1 and 6a1, elastin and ﬁbronectin
1), (B) proﬁbrogenic cytokines (TGFβ-1 and PDGF-BB) and (C) matrix metalloproteinases (MMP-2 and -14) at mRNA level in the diﬀerent treatment groups. Two
missing z-normalized values for ﬁbronectin 1 are depicted in grey.
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release for at least 14 days. The platinum concentration reached in the
liver was 721 ± 23 ng/liver, reﬂecting the amount platinum con-
jugated to the carrier plus the amount of platinum conjugated to in-
tracellular products (most likely glutathione conjugates) following the
release of Y27632 from the carrier. The steady state concentration in
the ﬁbrotic livers of mice that received microspheres containing pPB-
HSA was 121 ± 28.3 ng/liver, as determined by ELISA in a previous
study [15], which is in the same range given the fact that 5 molecules of
Y27632 are attached to each carrier molecule. Since our main objective
was to demonstrate the presence of our construct in the liver using ICP-
MS rather than to prove speciﬁc targeting, we did not consider platinum
concentrations in oﬀ-target organs.
The key question was whether these levels, obtained at the target
site after slow release from a subcutaneous depot, were high enough to
reach therapeutic concentrations to exert an antiﬁbrotic eﬀect. Clearly,
the gene array showed a reduction in gene expression levels of several
ECM proteins, proﬁbrotic cytokines and matrix metalloproteinases
(MMPs), and additionally a decrease in collagen I&III protein expres-
sion in Mdr2−/− mice that received microspheres containing pPB-
MSA-Y27632. These data convincingly demonstrate an important
pharmacological eﬀect of Y27632 at the target site.
The mechanism of the antiﬁbrotic eﬀect of Y27632 may be very
complex. According to all our gene array data, this could either be re-
lated to the reduced expression of proﬁbrotic cytokines, or the con-
sequence of reduced expression of MMPs. Evidently, mechanistic stu-
dies at the protein level are necessary in order to gain more insight in
the involved proﬁbrotic and pro-resolution factors. MMPs are involved
in the maintenance of the ECM and processes of tissue repair. These
proteinases not only resolve the excess matrix, but certain MMPs can
have proﬁbrotic functions as well [34]. For example, both MMP-2 and
MMP-14 were reported to be antiﬁbrotic via degradation of ECM pro-
teins [34,35], while other studies demonstrated contribution to ﬁbrosis
via proliferation of stellate cells [36] or by releasing transforming
growth factor beta 1 (TGFβ-1) [37].
In conclusion, we demonstrated that Y27632, when coupled to pPB-
MSA and incorporated in subcutaneous polymeric microspheres, is
pharmacologically active at the target site, i.e. within the ﬁbrotic liver.
This pharmacological eﬀect was observed 7 days after the microsphere
administration. Equimolar dosages of Y27632 were ineﬀective, showing
the relevance of our combined targeting - sustained release approach.
Polymeric microspheres may be suitable for the patient-friendly de-
livery of therapeutic proteins such as pPB-MSA-Y27632.
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